Tempus Announces Seven Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2023

April 14, 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced seven abstracts were accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 14-19, in Orlando, Florida. Tempus researchers will demonstrate how the company's AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.

"Tempus is excited to return to AACR and join the oncology research community in presenting our newest research, including how insights generated from our multimodal library led to an ongoing study exploring potential label expansion for a therapeutic for patients with PALB2 mutated tumors," said Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus.

This year, Tempus is sharing its latest collaborative scientific and clinical research findings via seven poster presentations. Highlights include:

- **Poster Presentation (3148): Leveraging scale in precision oncology to measure pathway activation and detect genetic drivers in a large, real-world pan-cancer cohort**
  - **Session Date & Time**: Monday, April 17, 2023; 1:30 p.m. – 5:00 p.m. ET
  - **Location**: Poster Section 33
  - **Overview**: Cancer tumorigenesis and progression are driven by genetic and epigenetic alterations, giving rise to transcriptional and pathway dysregulation. The Tempus team developed a machine learning platform that integrates DNA alterations and RNA expression data to measure the activation states of oncogenic signaling pathways and characterize novel genetic alterations that may cause pathway dysregulation, and tested it on Tempus' multimodal database. Assessing both the level of pathway disruption and underlying genomic drivers may provide a more comprehensive understanding of tumor biology than assessing either factor alone.

- **Poster Presentation (CT055): PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors**
  - **Session Date & Time**: Monday, April 17, 2023; 9:00 a.m. – 12:30 p.m. ET
  - **Location**: Poster Section 46
  - **Overview**: PARP inhibitors have demonstrated efficacy in treating solid tumors with homologous recombination deficiency, the inability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway. While *BRCA1/2* are instrumental to HRR, multiple genes, including *PALB2*, impact the HRR pathway. No clinically approved therapies specifically targeting PALB2 currently exist, however emerging evidence suggests that patients with germline or somatic *PALB2* mutations may benefit from PARP inhibitor treatment. Tempus molecular data tracking (integrated NGS and EMR data) and the TIME Trial Program (rapid match of patients to Just in TIME sites for clinical trials), enabled patient identification and prescreening for this trial.

To learn more, visit https://www.tempus.com/events/aacr-2023/.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.